News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
STAMFORD, Conn. , March 30, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Proposed Offering of Common Stock
STAMFORD, Conn. , March 29, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the 16th Annual Needham Healthcare Conference
STAMFORD, Conn. , March 28, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p < 0.0019)                        Met secondary endpoint in quality of life domains versus placebo after eight-week  treatment period (p < 0.0007)     I.V.
View HTML
Toggle Summary Cara Therapeutics to Present at March Medical Meetings
STAMFORD, Conn. , March 13, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
- Conference call today at 4:30 p.m. ET -
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
STAMFORD, Conn. , March 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Completes Planned Enrollment of Eight-Week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
- Part A of the trial will evaluate three doses of I.V. CR845 versus placebo in 160 dialysis patients   - - Top-line data expected in first quarter of 2017  - STAMFORD, Conn. , Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the 28th Annual Piper Jaffray Healthcare Conference
STAMFORD, Conn. , Nov. 22, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the Stifel 2016 Healthcare Conference
STAMFORD, Conn. , Nov. 08, 2016 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML